Journal of International Psychiatry

[Abstract] Objective: To compare the clinical efficacy of vasodilator (nitrate) + antidepressant (fluoxetine hydrochloride capsule) in the treatment of coronary heart disease (CHD) with depression. Methods: 900 cases of coronary heart disease patients with depression in our hospital from June 2019 to June 2020 were selected as the observation objects. According to the principle of double-blind randomized control, they were divided into two groups, one group was set as the conventional group (only using vasodilators), the other group was set as the study group (vasodilators + antidepressants). Each group had 450 cases. Results: the levels of TNF - α, CRP and IL-8 in the study group were significantly lower than those in the conventional group (P < 0.05); the scores of each dimension and total score of SAQ Seattle Angina scale in the study group were significantly higher than those in the conventional group (P < 0.05); the SDS depression score in the study group was lower than that in the conventional group (P < 0.05); the adverse cardiovascular events in the study group were less than those in the conventional group (P < 0.05). Conclusion: compared with the effect of vasodilator alone, combined with antidepressants in the treatment of coronary heart disease patients with depression can better reduce the level of inflammation, relieve the symptoms of depression, promote the improvement of their quality of life, and fewer adverse cardiovascular events, with high safety, worthy of clinical attention and wide promotion.

[Key words] vasodilators; antidepressants; coronary heart disease; depression; clinical efficacy